Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy

J Clin Oncol. 2010 Dec 20;28(36):e756-8. doi: 10.1200/JCO.2010.30.5011. Epub 2010 Sep 20.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / therapy*
  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Cetuximab
  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / therapy*
  • Humans
  • Male
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins / genetics*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins
  • Cetuximab